292 related articles for article (PubMed ID: 18294294)
21. Ifosfamide, methotrexate, etoposide, and prednisolone (IMEP) plus L-asparaginase as a first-line therapy improves outcomes in stage III/IV NK/T cell-lymphoma, nasal type (NTCL).
Kim M; Kim TM; Kim KH; Keam B; Lee SH; Kim DW; Lee JS; Jeon YK; Kim CW; Heo DS
Ann Hematol; 2015 Mar; 94(3):437-44. PubMed ID: 25300500
[TBL] [Abstract][Full Text] [Related]
22. L-asparaginase-based regimens followed by allogeneic hematopoietic stem cell transplantation improve outcomes in aggressive natural killer cell leukemia.
Jung KS; Cho SH; Kim SJ; Ko YH; Kang ES; Kim WS
J Hematol Oncol; 2016 Apr; 9():41. PubMed ID: 27091029
[TBL] [Abstract][Full Text] [Related]
23. High-dose methotrexate, etoposide, dexamethasone and pegaspargase (MEDA) combination chemotherapy is effective for advanced and relapsed/refractory extranodal natural killer/T cell lymphoma: a retrospective study.
Ding H; Chang J; Liu LG; Hu D; Zhang WH; Yan Y; Ma LY; Li ZC; Ma YJ; Hao SG; Tao R
Int J Hematol; 2015 Aug; 102(2):181-7. PubMed ID: 25997870
[TBL] [Abstract][Full Text] [Related]
24. A phase II prospective study of the "Sandwich" protocol, L-asparaginase, cisplatin, dexamethasone and etoposide chemotherapy combined with concurrent radiation and cisplatin, in newly diagnosed, I/II stage, nasal type, extranodal natural killer/T-cell lymphoma.
Jiang M; Zhang L; Xie L; Zhang H; Jiang Y; Liu WP; Zhang WY; Tian R; Deng YT; Zhao S; Zou LQ
Oncotarget; 2017 Jul; 8(30):50155-50163. PubMed ID: 28404973
[TBL] [Abstract][Full Text] [Related]
25. Successful treatment of extranodal natural killer/T-cell lymphoma, nasal type, complicated by severe hemophagocytic syndrome, with dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide chemotherapy followed by autologous stem cell transplant.
Inoue D; Nagai Y; Takiuchi Y; Nagano S; Arima H; Kimura T; Shimoji S; Mori M; Togami K; Tabata S; Yanagita S; Matsushita A; Nagai K; Maruoka H; Imai Y; Suzuki R; Takahashi T
Leuk Lymphoma; 2010 Apr; 51(4):720-3. PubMed ID: 20233057
[No Abstract] [Full Text] [Related]
26. Using etoposide + dexamethasone-based regimens to treat nasal type extranodal natural killer/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis.
Wei L; Yang L; Cong J; Ye J; Li X; Yao N; Yang J; Ding J; Wang J
J Cancer Res Clin Oncol; 2021 Mar; 147(3):863-869. PubMed ID: 33025280
[TBL] [Abstract][Full Text] [Related]
27. Successful full-dose DeVIC therapy in a patient with advanced-stage extranodal natural killer/T-cell lymphoma refractory to L-asparaginase.
Watanabe J; Makita S; Ito Y; Hatta S; Suzuki T; Yuda S; Maeshima AM; Fukuhara S; Munakata W; Suzuki T; Maruyama D; Kim SW; Izutsu K
Ann Hematol; 2018 Sep; 97(9):1739-1740. PubMed ID: 29663028
[No Abstract] [Full Text] [Related]
28. Pralatrexate as a bridge to allogeneic hematopoietic stem cell transplantation in a patient with advanced-stage extranodal nasal-type natural killer/T cell lymphoma refractory to first-line chemotherapy: a case report.
Liu YC; Lin TA; Wang HY; Ko PS; Liu CJ; Hsiao LT; Chien SH; Gau JP
J Med Case Rep; 2020 Mar; 14(1):43. PubMed ID: 32183896
[TBL] [Abstract][Full Text] [Related]
29. Chemorefractory extranodal nasal-type natural-killer/T-cell lymphoma with great response to pembrolizumab in a young patient: a case report.
Adabifirouzjaei F; Khazai B; Azami G; Shoja-E-Razavi G
J Med Case Rep; 2021 Oct; 15(1):539. PubMed ID: 34702349
[TBL] [Abstract][Full Text] [Related]
30. Concurrent Chemoradiation Therapy Followed by Consolidation Chemotherapy for Localized Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type.
Oh D; Ahn YC; Kim SJ; Kim WS; Ko YH
Int J Radiat Oncol Biol Phys; 2015 Nov; 93(3):677-83. PubMed ID: 26461010
[TBL] [Abstract][Full Text] [Related]
31. Dexamethasone, methotrexate, ifosfamide, L-asparaginase and etoposide (SMILE) chemotherapy for relapsed or refractory adult lymphoblastic lymphoma.
Chang WJ; Ko YH; Kim SJ; Kim WS
Leuk Lymphoma; 2014 Sep; 55(9):2196-8. PubMed ID: 24308435
[No Abstract] [Full Text] [Related]
32. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
33. "Sandwich" protocol based on modified SMILE regimen for children with newly extranodal NK/T cell lymphoma, nasal type: a single-arm, single-center clinical study.
Shen CQ; He GQ; Wan Z; Lin C; Yang X; Lu XX; Zhu YP; Gao J; Guo X
Ann Hematol; 2023 Nov; 102(11):3143-3152. PubMed ID: 37486391
[TBL] [Abstract][Full Text] [Related]
34. Improved prognosis of extranodal NK/T cell lymphoma, nasal type of nasal origin but not extranasal origin.
Yamaguchi M; Suzuki R; Miyazaki K; Amaki J; Takizawa J; Sekiguchi N; Kinoshita S; Tomita N; Wada H; Kobayashi Y; Niitsu N; Ando T; Maeda T; Saito B; Matsuoka H; Sakai R; Kubota N; Masaki Y; Kameoka Y; Asano N; Oguchi M; Katayama N
Ann Hematol; 2019 Jul; 98(7):1647-1655. PubMed ID: 31001658
[TBL] [Abstract][Full Text] [Related]
35. Methotrexate-associated lymphoproliferative disorder presenting as extranodal NK/T-cell lymphoma arising in the lungs.
Tajima S; Takanashi Y; Koda K; Fukayama M
Pathol Int; 2015 Dec; 65(12):661-5. PubMed ID: 26459854
[TBL] [Abstract][Full Text] [Related]
36. Retrospective study of modified SMILE chemotherapy for advanced-stage, relapsed, or refractory extranodal natural killer (NK)/T cell lymphoma, nasal type.
Yang L; Liu H; Xu XH; Wang XF; Huang HM; Shi WY; Jiang SH
Med Oncol; 2013 Dec; 30(4):720. PubMed ID: 24062259
[TBL] [Abstract][Full Text] [Related]
37. Combined gemcitabine, cisplatin, dexamethasone, methotrexate, and pegaspargase (GDP-ML) for patients with newly diagnosed extranodal natural killer/T cell lymphoma, nasal type: a single arm, single center, prospective phase 2 study.
Wei C; Cao X; Zhang W; Zhang Y; Wang W; Zhang L; Yang C; Feng J; Cai H; Chen M; Mao Y; Zhou D
Ann Hematol; 2020 Dec; 99(12):2801-2809. PubMed ID: 32399707
[TBL] [Abstract][Full Text] [Related]
38. Extra-nodal natural killer/T cell lymphoma in elderly patients: the impact of aging on clinical outcomes and treatment tolerability.
Kim SM; Park S; Oh DR; Ahn YC; Ko YH; Kim SJ; Kim WS
Ann Hematol; 2016 Mar; 95(4):581-91. PubMed ID: 26729202
[TBL] [Abstract][Full Text] [Related]
39. Comparative Study of L-Asparaginase-Based LOP Regimen Over CHOP Regimen Before Radiotherapy for Stage IIE Extranodal Nasal Type NK/T Cell Lymphoma: A Study of 2 Centers.
Huang L; Yuan B; Wu H; Chu H; Liu Y; Wu S; Li H; Lu H; Chen H
Clin Lymphoma Myeloma Leuk; 2017 Mar; 17(3):152-158. PubMed ID: 28215935
[TBL] [Abstract][Full Text] [Related]
40. Midtreatment ¹⁸F-FDG PET/CT Scan for Early Response Assessment of SMILE Therapy in Natural Killer/T-Cell Lymphoma: A Prospective Study from a Single Center.
Khong PL; Huang B; Lee EY; Chan WK; Kwong YL
J Nucl Med; 2014 Jun; 55(6):911-6. PubMed ID: 24819420
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
